 "Aurobindo Pharma")
Aurobindo Pharma continues to be under pressure on the bourses owing to the US Food and Drug Administration’s (US FDA’s) observations to its unit-IV facility at Hyderabad.
On Monday, Aurobindo confirmed that the unit has received nine observations between February 12 and February 20. As a result, some caution will prevail till complete clearance is given to the unit, even as analysts say the observations are not very serious.
The firm’s unit-IV makes injectables and accounts for a third of Aurobindo’s pending abbreviated new drug applications (ANDAs), analysts said. An ANDA contains data, which is submitted to the
On Monday, Aurobindo confirmed that the unit has received nine observations between February 12 and February 20. As a result, some caution will prevail till complete clearance is given to the unit, even as analysts say the observations are not very serious.
The firm’s unit-IV makes injectables and accounts for a third of Aurobindo’s pending abbreviated new drug applications (ANDAs), analysts said. An ANDA contains data, which is submitted to the
